A Phase 4 interventional study of peginterferon alfa-2a [Pegasys] and ribavirin in Hepatitis C, Chronic, sponsored by Hoffmann-La Roche. Completed at 93 sites in Russian Federation. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-01-20.
Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. peginterferon alfa-2a · Hepatitis C, Chronic.
Among the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic, this one has the largest enrollment, is one of 4 that started in 2002, is one of 48 in phase 4, and was the 50th registered.
950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.
Browse Hepatitis C, Chronic studies →None of the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →
peginterferon alfa-2a: first FDA approval 2002 (PEGASYS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
83 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 12 · Phase 3 20 · Phase 4 48
First in 2000; this study’s year is marked. 4 started in 2002.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 6,661 is above the median of 90 across 696 interventional studies indexed under Hepatitis C, Chronic.
Median enrollment 129 across the 83 interventional studies. Of the 75 that completed or were terminated, 38 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 83 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
86 studies in Hepatitis C, Chronic by Hoffmann-La Roche: none open now, none under way, none of them phase 3. Of 84 finished, 48 (57%) have results posted.
Among the 86 studies in Hepatitis C, Chronic by Hoffmann-La Roche, this one has the largest enrollment of the 59 interventional ones that give a count, is one of 3 that started in 2002, is one of 29 in phase 4, and was the 30th registered.
Hoffmann-La Roche’s Hepatitis C, Chronic studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 86 in Hepatitis C, Chronic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This single arm study will evaluate the safety and tolerability of ribavirin in combination with PEGASYS in patients with chronic hepatitis C. Patients will receive ribavirin 800mg, or 1000-1200mg po daily, according to HCV genotype and body weight (\< and >75kg)in combination with PEGASYS 180micrograms sc weekly. The anticipated time on study treatment is 3-12 months, and the target sample size is >500 individuals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: peginterferon alfa-2a [Pegasys] · Drug: ribavirin
180micrograms sc weekly for 12-48 weeks
800mg, or 1000-1200mg, po daily (dependent on HCV genotype and body weight)
Number of Participants With Non-Serious Adverse Events (AEs) And Serious Adverse Events (SAEs)
An AE was any untoward medical occurrence in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Number of participants with non-serious AEs were exclusive of serious AEs.
Time frame: From signing of informed consent up to end of study (up to Week 72)
Percentage of Participants With Sustained Virological Response (SVR) at 24 Weeks After End of Therapy
SVR at 24 weeks after end of therapy was defined as a negative result of HCV Ribonucleic Acid (HCV RNA) qualitative assay 24 weeks after end of therapy. Percentage of participants with SVR was calculated as \[number of participants with negative results of HCV RNA qualitative assay 24 weeks after end of therapy divided by the total number of participants analyzed\] multiplied by 100. The participants who failed to undergo tests at 24 weeks after completion of therapy were considered not amenable to therapy.
Time frame: 24 weeks after end of therapy (Week 72)
Percentage of Participants With Undetectable HCV RNA at Weeks 12, 24 and 48 After Therapy Initiation
HCV RNA levels of \< 50 International Units per milliliter (IU/mL) were defined as undetectable HCV RNA. The percentage of participants with undetectable HCV RNA was calculated as \[number of participants with undetectable HCV RNA divided by the total number of participants analyzed\] multiplied by 100 for Weeks 12, 24 and 48.
Time frame: Weeks 12,24 and 48 After Therapy Initiation
Percentage of Participants With Change in Hemoglobin Level
Change in hemoglobin level (compared to baseline) was reported as "significant decrease", "Normal" (no change), "Increase", "Decrease", and "Missing". Significant decrease was defined as per Investigator's discretion.
Time frame: Baseline, Weeks 2, 4, 8, 12, 24, 36, 48 and follow-up Weeks 4 (Week 52), 12 (Week 60), and 24 (Week 72)
A total of 7799 participants were screened, of which 6661 participants were included in the study.
| Milestone | Ribavirin + Peginterferon Alfa-2a |
|---|---|
| Started | 6661 |
| Completed | 4334 |
| Not completed | 2327 |
| Withdrew: Adverse event | 67 |
| Withdrew: Pregnancy | 7 |
| Withdrew: Withdrawal by subject | 308 |
| Withdrew: Lost to follow-up | 44 |
| Withdrew: Other | 27 |
| Withdrew: Missing | 1874 |
An AE was any untoward medical occurrence in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Number of participants with non-serious AEs were exclusive of serious AEs.
| Participants | Ribavirin + Peginterferon Alfa-2a |
|---|---|
| Non Serious AEs | 2058 |
| SAEs | 67 |
SVR at 24 weeks after end of therapy was defined as a negative result of HCV Ribonucleic Acid (HCV RNA) qualitative assay 24 weeks after end of therapy. Percentage of participants with SVR was calculated as \[number of participants with negative results of HCV RNA qualitative assay 24 weeks after end of therapy divided by the total number of participants analyzed\] multiplied by 100. The participants who failed to undergo tests at 24 weeks after completion of therapy were considered not amenable to therapy.
| Percentage of Participants | Ribavirin + Peginterferon Alfa-2a |
|---|---|
| Percentage of Participants With Sustained Virological Response (SVR) at 24 Weeks After End of Therapy | 50.9 |
HCV RNA levels of \< 50 International Units per milliliter (IU/mL) were defined as undetectable HCV RNA. The percentage of participants with undetectable HCV RNA was calculated as \[number of participants with undetectable HCV RNA divided by the total number of participants analyzed\] multiplied by 100 for Weeks 12, 24 and 48.
| Percentage of Participants | Ribavirin + Peginterferon Alfa-2a |
|---|---|
| Week 12 | 58.8 |
| Week 24 | 69.7 |
| Week 48 | 24.8 |
Change in hemoglobin level (compared to baseline) was reported as "significant decrease", "Normal" (no change), "Increase", "Decrease", and "Missing". Significant decrease was defined as per Investigator's discretion.
| Percentage of Participants | Ribavirin + Peginterferon Alfa-2a |
|---|---|
| Week 2, Significant decrease | 13.5 |
| Week 2, Normal | 32.4 |
| Week 2, Increase | 11.7 |
| Week 2, Decrease | 32.3 |
| Week 2, Missing | 10.0 |
| Week 4, Significant decrease | 27.9 |
| Week 4, Normal | 21.0 |
| Week 4, Increase | 6.9 |
| Week 4, Decrease | 35.1 |
| Week 4, Missing | 9.1 |
| Week 8, Significant decrease | 35.4 |
| Week 8, Normal | 15.3 |
| Week 8, Increase | 5.1 |
| Week 8, Decrease | 31.5 |
| Week 8, Missing | 12.8 |
| Week 12, Significant decrease | 38.9 |
| Week 12, Normal | 15.2 |
| Week 12, Increase | 4.7 |
| Week 12, Decrease | 30.1 |
| Week 12, Missing | 11.1 |
| Week 24, Significant decrease | 34.9 |
| Week 24, Normal | 13.6 |
| Week 24, Increase | 4.6 |
| Week 24, Decrease | 25.4 |
| Week 24, Missing | 21.5 |
| Week 36, Significant decrease | 16.2 |
| Week 36, Normal | 4.1 |
| Week 36, Increase | 1.7 |
| Week 36, Decrease | 9.1 |
| Week 36, Missing | 69.0 |
| Week 48, Significant decrease | 13.7 |
| Week 48, Normal | 3.8 |
| Week 48, Increase | 1.7 |
| Week 48, Decrease | 7.7 |
| Week 48, Missing | 73.1 |
| Follow-up Week 4, Significant decrease | 11.5 |
| Follow-up Week 4, Normal | 18.5 |
| Follow-up Week 4, Increase | 6.8 |
| Follow-up Week 4, Decrease | 19.6 |
| Follow-up Week 4, Missing | 43.7 |
| Follow-up Week 12, Significant decrease | 5.8 |
| Follow-up Week 12, Normal | 23.0 |
| Follow-up Week 12, Increase | 10.2 |
| Follow-up Week 12, Decrease | 16.1 |
| Follow-up Week 12, Missing | 44.8 |
| Follow-up Week 24, Significant decrease | 4.7 |
| Follow-up Week 24, Normal | 27.5 |
| Follow-up Week 24, Increase | 12.2 |
| Follow-up Week 24, Decrease | 15.5 |
| Follow-up Week 24, Missing | 40.2 |
Collected over From signing of informed consent up to end of study (up to Week 72). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ribavirin + Peginterferon Alfa-2a | — | 67/6,661 (1%) | 1,674/6,661 (25.1%) |
| Event | Ribavirin + Peginterferon Alfa-2a |
|---|---|
| Pyelonephritis acuteInfections and infestations | 2/6661 |
| CholecystitisHepatobiliary disorders | 2/6661 |
| CholelithiasisHepatobiliary disorders | 2/6661 |
| Hepatic cirrhosisHepatobiliary disorders | 2/6661 |
| Hepatic failureHepatobiliary disorders | 2/6661 |
| Myocardial infarctionCardiac disorders | 2/6661 |
| Completed suicidePsychiatric disorders | 2/6661 |
| DepressionPsychiatric disorders | 2/6661 |
| AstheniaGeneral disorders | 2/6661 |
| Toxic skin eruptionSkin and subcutaneous tissue disorders | 2/6661 |
| Event | Ribavirin + Peginterferon Alfa-2a |
|---|---|
| AstheniaGeneral disorders | 905/6661 |
| Influenza like illnessGeneral disorders | 833/6661 |
| AnaemiaBlood and lymphatic system disorders | 459/6661 |
| PyrexiaGeneral disorders | 371/6661 |
| Weight loss poorMetabolism and nutrition disorders | 343/6661 |
Baseline population included all enrolled participants.
| Age, Continuous(Years) | Ribavirin + Peginterferon Alfa-2a |
|---|---|
| Mean | 34.21 ± 9.81 |
| Sex/Gender, Customized(Participants) | Ribavirin + Peginterferon Alfa-2a |
|---|---|
| Male | 4396 |
| Female | 2250 |
| Missing | 15 |
The record gives a start of Jun 2002, a primary completion of Jun 2012 and a completion of Jun 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2016, 3 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Peginterferon alfa-2a · Ribavirin